Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies after reporting favorable safety results from Phase 1 clinical trials in healthy volunteers. The therapy is designed to target demyelination and protect or restore myelin integrity, a key pathological feature of multiple sclerosis. The company submitted an Investigational New Drug application to the U.S. Food and Drug Administration in April 2026, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The Phase 1 studies demonstrated that LUCID-MS was generally well tolerated with a favorable safety profile, supporting the decision to move forward. Quantum BioPharma believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation. To strengthen operational support for the program, the company is planning a partnership with Allucent and engaging neurological specialists.
Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it focuses on LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also owns 19.84% of Unbuzzd Wellness Inc., which markets an over-the-counter version of unbuzzd, and retains royalty payments on sales. For more information, visit the company's newsroom at https://ibn.fm/QNTM.
The advancement of LUCID-MS represents a significant step toward a novel treatment for multiple sclerosis, a condition affecting millions worldwide. Current therapies primarily modulate the immune system to reduce inflammation, but they do not directly repair myelin damage. LUCID-MS's approach could potentially halt or reverse disease progression, offering hope for patients with limited options. The Phase 2 trial will assess efficacy and further safety in the target population, with results expected to inform the therapy's future development and regulatory pathway.
